Evidence map›Paper›PMID 41329290›Full record

ArticlePediatric nephrology (Berlin, Germany)2026

Comparison of efficacy of single-dose and double-dose rituximab in the treatment of refractory nephrotic syndrome in children: a retrospective study.

Junli Wang, Zhihong Hao, Lina Wang, Li Yu, Huiyang Wang, Qiaoqun Ou, Shengyou Yu

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. APRIL: spring forward also for IgA vasculitis nephritis in children.Pediatric nephrology (Berlin, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Junli WangDepartment of Pediatrics, the Second Affiliated Hospital of South China University of Technology, Guangzhou, 510180, Guangdong, China.ORCID http://orcid.org/0009-0009-0846-1921
Zhihong HaoDepartment of Pediatrics, the Second Affiliated Hospital of South China University of Technology, Guangzhou, 510180, Guangdong, China.
Lina WangDepartment of Pediatrics, the Second Affiliated Hospital of South China University of Technology, Guangzhou, 510180, Guangdong, China.
Li YuDepartment of Pediatrics, the Second Affiliated Hospital of South China University of Technology, Guangzhou, 510180, Guangdong, China.
Huiyang WangDepartment of Pediatrics, the Second Affiliated Hospital of South China University of Technology, Guangzhou, 510180, Guangdong, China.
Qiaoqun OuDepartment of Pediatrics, the Second Affiliated Hospital of South China University of Technology, Guangzhou, 510180, Guangdong, China.
Shengyou YuDepartment of Pediatrics, the Second Affiliated Hospital of South China University of Technology, Guangzhou, 510180, Guangdong, China. eyyushengyou@scut.edu.cn.ORCID http://orcid.org/0000-0001-8566-0400

Funding

The National Key Research and Development Program of China 2022YFC2705104The National Key Research and Development Program of China No. 2022YFC2705100The National Key Research and Development Program of China No. 2022YFC2705103
6 · The paper itself

Abstract

backgroundThe objective was to compare the efficacy of single-dose versus double-dose rituximab (RTX) regimens in children with frequently relapsing/steroid-dependent nephrotic syndrome (FRNS/SDNS).

methodsThis retrospective study analyzed 53 pediatric FRNS/SDNS patients treated at Guangzhou First People's Hospital from January 2020 to November 2024. Patients received either single-dose (n = 36, one RTX infusion at month 0) or double-dose (n = 17, two infusions at 0 and 3 months) RTX (375 mg/m

resultsAt the 6-month and 12-month follow-ups, there were no differences in relapse rates between the single-dose and double-dose groups (31% (11/36) vs. 47% (8/17) at 6 months; 36% (13/36) vs. 53% (9/17) at 12 months). Furthermore, at the 12-month follow-up, no differences were observed between the single-dose and double-dose groups in the annual relapse frequency (0.7 ± 1.1 vs. 1.0 ± 1.2 times/year) or the cumulative prednisone usage (0.21 ± 0.12 vs. 0.22 ± 0.14 mg/(kg·d)). Kaplan-Meier analysis revealed no difference in relapse-free survival between groups (log-rank test, χ

conclusionSingle-dose and double-dose RTX regimens demonstrate comparable efficacy in maintaining remission in pediatric FRNS/SDNS patients over 12 months. The extended-interval double-dose regimen provides no significant clinical advantage, suggesting that a single-dose strategy may be sufficient while reducing treatment costs.

Indexed as

Immunologic FactorsNephrotic SyndromeRituximabAdolescentChildChild, PreschoolDose-Response Relationship, DrugFemaleFollow-Up StudiesGlucocorticoidsHumansImmunosuppressive AgentsMalePrednisoneRecurrenceRetrospective StudiesGlucocorticoidsImmunologic FactorsImmunosuppressive AgentsPrednisoneRituximabChildrenFRNSNephrotic syndromeRituximabSSNS

Identifiers

PMID41329290

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.